DYAI (Dyadic International) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DYAI Dyadic International Inc DYAI
37 GF Score
Price $1.49
GF Value $0.74
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dyadic International Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

DYAI
37GF Score
Dyadic International Inc DYAI
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dyadic International (DYAI) Overvalued in 2026?

Based on GuruFocus' analysis, Dyadic International stock appears to be overvalued. The current stock price of $1.49 is trading 100.9% above its estimated GF Value™ of $0.74. GuruFocus considers Dyadic International to be Significantly Overvalued.

Key valuation signals for DYAI:

  • Interest Received:
  • GF Value™: $0.74 vs. price of $1.49 (100.9% above fair value)
  • GF Score™: 37/100 with 7 warning signs

No single metric tells the full story. See the DYAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dyadic International Business Description

Address 1044 North U.S. Highway One, Suite 201, Jupiter, FL, USA, 33477
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
37GF Score

Get the complete analysis for DYAI

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$0.74
GF Value